Evidence map›Paper›PMID 40563681›Full record

ArticleCancers2025

Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis.

Sunidhi Jaiswal, Siamak Amirfakhri, Javier Bravo, Keita Kobayashi, Abhijit Aithal, Sumbal Talib, Kavita Mallya, Maneesh Jain, Aaron M Mohs, Robert M Hoffman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Distinct O-Linked Glycosylation Systems in Signaling and Immune Regulation.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sunidhi JaiswalDepartment of Surgery, University of California San Diego, La Jolla, CA 92093, USA.
Siamak AmirfakhriDepartment of Surgery, University of California San Diego, La Jolla, CA 92093, USA.
Javier BravoDepartment of Surgery, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9636-6717
Keita KobayashiDepartment of Surgery, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0009-0004-9177-2352
Abhijit AithalDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA.ORCID 0000-0001-9035-7529
Sumbal TalibDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68105, USA.ORCID 0000-0001-7141-740X
Kavita MallyaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA.
Maneesh JainDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA.ORCID 0000-0002-2020-3687
Aaron M MohsDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA.ORCID 0000-0002-9353-5404
Robert M HoffmanDepartment of Surgery, University of California San Diego, La Jolla, CA 92093, USA.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA.ORCID 0000-0001-9470-9317
Michael BouvetDepartment of Surgery, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-0086-2159

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic CancerR01CA256973 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Surinder K. Batra, Michael Bouvet · 2022 to 2026
$2.2M
Preclinical development of a novel antibody conjugate for intraoperative detection of pancreatic cancerR01CA259080 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aaron M. Mohs · 2022 to 2026
$1.8M
BLRD VA I01 BX003856National Institute of Health Training Grant T32CA121938NCI NIH HHS R01 CA256973NCI NIH HHS R01 CA259080NCI NIH HHS T32 CA121938NIH HHS R01 CA256973NIH HHS R01 CA259080
6 · The paper itself

Abstract

BACKGROUND/

objectivesPancreatic cancer is the fourth leading cause of deaths related to cancer. It is a highly aggressive malignancy and often metastasizes quickly to other parts of the body and organs. The most effective cure is surgical resection, which also is limited by tumor identification and clear tumor margin visualization. Previously, we used MUC4 antibodies labeled with IRDye800CW (anti-MUC4-IR800) to target primary human pancreatic cancer in orthotopic cell line mouse models.

methodsIn the present study, we established a pancreatic cancer liver metastasis mouse model by implanting a tumor fragment in the liver and a peritoneal carcinomatosis mouse model by injecting pancreatic cancer cells interperitoneally. Once the tumors were established, anti-MUC4-IR800 was administered to the mice by tail vein injection. Laparotomy was performed and tumors were imaged under white-light and near-infrared (NIR) fluorescence with the Pearl Small Animal Imaging System.

resultsNIR imaging after 72 h shows the bright targeting of pancreatic cancer metastasis in both mouse models with high tumor-to-background ratios.

conclusionsAnti-MUC4-IR800 was able to successfully target and brightly label metastatic pancreatic cancer as small as 1 mm. Future clinical applications of the results of the present study are discussed.

Indexed as

antibodyfluorescenceliver metastasismouse modelMUC4mucinsNIR Dyeorthotopicpancreatic cancerperitoneal carcinomatosistumor targeting

Identifiers

PMID40563681
PMCPMC12191291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.